Abstract
The sodium glucose cotransporter 2 (SGLT2) is expressed primarily in the kidneys and is involved in the reabsorption of filtered glucose in the renal tubule. Clinical trials of SGLT2 inhibitors in patients with type 2 diabetes mellitus demonstrate a significant clinical effect in decreasing serum glucose, hemoglobin A1C, body weight, systolic blood pressure, improving β-cell function, and minimizing the risk of hypoglycemia. This report reviews the potentially beneficial effects of SGLT2 inhibitors in type 2 diabetes mellitus, specifically focusing on canagliflozin, the only SGLT2 inhibitor approved for use in the United States.
Keywords: Antihyperglycemic agents, body weight loss, canagliflozin, hypoglycemia, renal threshold for glucose, SGLT2 inhibitor, type 2 diabetes mellitus, urinary glucose excretion.
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition with Canagliflozin in Type 2 Diabetes Mellitus
Volume: 11 Issue: 3
Author(s): Sarmad Said and German T. Hernandez
Affiliation:
Keywords: Antihyperglycemic agents, body weight loss, canagliflozin, hypoglycemia, renal threshold for glucose, SGLT2 inhibitor, type 2 diabetes mellitus, urinary glucose excretion.
Abstract: The sodium glucose cotransporter 2 (SGLT2) is expressed primarily in the kidneys and is involved in the reabsorption of filtered glucose in the renal tubule. Clinical trials of SGLT2 inhibitors in patients with type 2 diabetes mellitus demonstrate a significant clinical effect in decreasing serum glucose, hemoglobin A1C, body weight, systolic blood pressure, improving β-cell function, and minimizing the risk of hypoglycemia. This report reviews the potentially beneficial effects of SGLT2 inhibitors in type 2 diabetes mellitus, specifically focusing on canagliflozin, the only SGLT2 inhibitor approved for use in the United States.
Export Options
About this article
Cite this article as:
Said Sarmad and Hernandez T. German, Sodium Glucose Co-Transporter 2 (SGLT2) Inhibition with Canagliflozin in Type 2 Diabetes Mellitus, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (3) . https://dx.doi.org/10.2174/187152571103140120103032
DOI https://dx.doi.org/10.2174/187152571103140120103032 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Depression and Self-Efficacy in Patients with Type 2 Diabetes in Northern Greece
Endocrine, Metabolic & Immune Disorders - Drug Targets Increased Paternal Age and Child Health and Development
Current Pediatric Reviews Cyclosporin A: A Therapeutic Strategy in Allergic Diseases
Letters in Drug Design & Discovery The Involvement of Uric Acid in the Pathogenesis of Preeclampsia
Current Hypertension Reviews Postprandial Hypertriglyceridaemia Revisited in the Era of Non-fasting Lipid Profiles: Executive Summary of a 2019 Expert Panel Statement
Current Vascular Pharmacology The Genetic Background of Cholesterol Gallstone Formation: An Inventory of Human Lithogenic Genes
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics
Current Drug Metabolism Reduction of Myocardial Ischemia-Reperfusion Injury with Pre- and Postconditioning: Molecular Mechanisms and Therapeutic Targets
Cardiovascular & Hematological Disorders-Drug Targets CEST MRI for Molecular Imaging of Brain Metabolites
Current Molecular Imaging (Discontinued) Genetics in Gestational Diabetes Mellitus: Association with Incidence, Severity, Pregnancy Outcome and Response to Treatment
Current Diabetes Reviews Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond
Current Medicinal Chemistry An Overview of Valuable Scientific Models for Diabetes Mellitus
Current Diabetes Reviews Novel Biomarkers Assessing Endothelial Dysfunction: Role of microRNAs
Current Topics in Medicinal Chemistry Metabolomic Biomarkers in Gynecology: A Treasure Path or a False Path?
Current Medicinal Chemistry Reproductive Health Indicators and Factors Affecting Menstrual Cycle Pattern among Sudanese Women with Thyroid Dysfunction
Current Women`s Health Reviews Genetic Association Studies in Diabetic Nephropathy
Current Diabetes Reviews Cardiovascular Effects of Metabolic Surgery on Type 2 Diabetes
Current Cardiology Reviews Prolonged Air Leak After Lung Resection
Current Respiratory Medicine Reviews Use of Sodium-Glucose Co-Transporter-2-Inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation
Current Drug Safety Effect of Oral Alkali Supplementation on Progression of Chronic Kidney Disease
Current Hypertension Reviews